METHYLON Injection

Methylprednisolone Sodium Succinate 125 mg


Methylon® 125 mg Powder for Injection, each vial contains : Methylprednisolone sodium succinate equivalent  to Methylprednisolone 125 mg.



Methylon® with Methylprednisolone sodium succinate (equivalent to Methyprednisolone) as active ingredient is available in 125 mg powder for injection.



  • Endocrine disorders : Primary or secondary adrenocortical insufficiency, acute adrenocortical insufficiency
  • Rheumatic disorders : As adjunctive therapy for short – term administration in : Post traumatic osteoarthritis, synovitis osteoarthritis, rheumatoid arthritis, acute and sub-acute bursitis; epicondylitis, acute non-specific tenosynovitis, acute gouty arthritis, psoriasis arthritis, and ankylosing spondylitis.
  • Collagen diseases : During an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematous, systemic dermatomyositis and acute rheumatic carditis.
  • Dermatologic disease : Pemphigus, severe erythema multiform, exfoliate dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe psoriasis and mycosis fungoides.
  • Allergic states : Bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity reactions.
  • Gastrointestinal disease : To tide the patient over a critical period of the disease in ulcerative colitis and regional enteritis.
  • Neoplastic disease : For palliative management of leukemia and lymphomas in adults and acute leukemia of childhood.
  • Edematous states : To induce diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
  • Nervous system : Acute exacerbation of multiple sclerosis.



Adult :                                  

Administered by IM/IV : 10 – 40 mg (base), repeated as needed.

  • For pulse therapy (large doses) : IV 30 mg (base)/kgBW administered minimum within 30 minutes. Doses can be repeated every 4 – 6 hours as needed.
  • For acute exacerbation at double sclerosis : IM/IV : 160 mg (base) per day during a week. Followed by 64 mg everyday during a month.
  • For acute vertebrae injury : IV 30 mg (base)/kgBW administered within 15 minutes, followed by 45 minutes infuse, 5.4 mg/kgBW/hour, during 23 hours.
  • Additional therapy for patient with AIDS related to pneumocystis carinii : IV 30 mg (base) twice a day from first to fifth day, 30 mg once a day from sixth to tenth day, 15 mg once a day from eleventh to twenty first day.

Baby and children :

  • Adrenocortical insufficiency : IM 117 mcg (0.117 mg) (base)/kgBW or 3.33 mg (base)/m2 body surface per day (in three divided dose) every third day or 39 – 58.5 mcg (0.039 – 0,0585 mg) (base) per kgBW or 1.11 – 1.66 mg (base)/m2 body surface once a day.
  • For acute vertebrae injury : IV 30 mg (base)/kgBW administered within 15 minutes, followed by 45 minutes infuse 5.4 mg/kgBW/hour during 23 hours.
  • Other indications : IM 139 – 835 mcg (0.139 – 0.835 mg) (base)/kgBW or 4.16 – 25 mg (base)/m2 body surface every 12 – 24 hours.
  • Additional therapy for AIDS related to Pneumocystis carinii :
      1. Children age ≤ 13 years : No certain dose determined.
      2. Children > 13 years : Same with adult’s doses.

Reconstitution procedure of Methylon® Powder for Injection :

Reconstitute powder by adding solvent (containing benzyl alcohol 0,9%), mix homogeneously. Direct IV can be given at least 1 min. After reconstitution, Methylon® can be stored for up to 48 hours at temperature below 30ºC.



  • Systemic fungal infection.
  • Patients with known hypersensitivity to the product and the constituents.
  • Premature babies : Providing long term in patients with duodenal ulcer, severe osteoporosis, patient with a history of psychosis, herpes, patient who were immunized.



  • Corticosteroids may mask some signs of infections, and new infections may appear during their use. The infection may be mild, but can be severe and at the time fatal.
  • Prolonged use of corticosteroids may produce posterior sub capsular cataracts, glaucoma with possible damage to the optic nerves and may enhance the establishment of secondary ocular infections due to fungi or viruses.
  • While on corticosteroids therapy, patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high doses, because of the possible hazards of neurological complications and a lack of antibody response.
  • Use in pregnancy : Since there is inadequate evidence of safety in human pregnancy, Methylprednisolone should be used in pregnancy only if clearly needed.
  • There is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis.
  • Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.
  • Large doses of Methylprednisolone can cause elevation of blood pressure, water and salt retention, increasing of potassium and calcium excretion, and reducing body immune against fungal, bacterial, and viral infection.



Methylon® Powder for Injection 125 mg       Box, 1 vial @ 125 mg + 1 ampoule solvent @ 2 ml   Reg. No. DKL0902341844A1





After reconstitution, Methylon® can be stored for up to 48 hours at temperature below 30oC.




Manufactured by :


Sidoarjo – Indonesia